Candidate nomination is not the end of molecular selection. The physical form carried into toxicology, formulation, manufacturing, and first-in-human studies can change solubility, stability, processability, analytical control, and development risk.
Triclinic Labs helps emerging pharmaceutical and biotechnology teams define the evidence needed at each stage. The work begins with the candidate, available material, prior data, dose and route, formulation plan, timeline, and the decision the program must support. Testing expands only when the result can change the development path.
Physical-form development should progress with the molecule. Early work identifies immediate risk; later work selects and controls the form that can move through process development, formulation, cGMP manufacture, and clinical supply.
The scope is stage-appropriate. A limited-material candidate does not need every possible experiment. It needs the smallest defensible program that identifies material risk and makes the next decision clearer.
These are flexible starting scopes. Each program is adjusted for molecule properties, available material, prior data, development phase, regulatory use, and the evidence needed to move forward.
Best for: Candidate nomination and limited-API programs that need an early risk picture.
Assessment may include:
Deliverable: Development Risk Assessment with prioritized recommendations for the next experiments.
Best for: Programs ready to compare practical form options and select a development path.
The scoped combination may include:
Deliverable: Recommended development form, alternative-form strategy, and risk register.
Best for: Programs that must convert form selection into a controlled development and clinical-supply strategy.
The program may include:
Deliverable: Integrated form-control strategy with methods, process knowledge, cGMP evidence, and defined lifecycle risks.
Early enough to avoid carrying an uncontrolled or unstable form into toxicology, formulation, or larger material commitments. The depth of screening should match the phase and available API.
Explore polymorph screening and selectionIonization, crystallinity, solubility, stability, dose, route, and formulation needs determine whether the next step is free-form, salt, cocrystal, or amorphous development.
Explore pharmaceutical salt screeningForm selection becomes useful only when crystallization, isolation, drying, particle attributes, and process stresses can be controlled at the required scale.
Explore crystallization method developmentThe analytical strategy should support identification, quantitation where needed, formulation compatibility, cGMP testing, release, stability, and scientifically defensible regulatory decisions.
Explore cGMP XRPD servicesTriclinic can combine the services below around the candidate-to-IND decision instead of treating each technique or screen as an isolated purchase.
Identify alternate forms, compare risk, and select the evidence needed for the development phase.
View serviceEvaluate property-improvement strategies when the free form does not provide an acceptable balance.
View cocrystal servicesAssess amorphous feasibility, recrystallization risk, polymer strategy, and solid-dispersion development.
View serviceTranslate form selection into reproducible process control and resolve form or particle problems during scale-up.
View serviceConnect solubility, moisture response, thermal behavior, spectroscopy, microscopy, diffraction, and other evidence to the development decision.
View analytical techniquesSupport method development, cGMP form testing, release, stability, and regulated documentation when the program reaches that stage.
View cGMP servicesThese Triclinic Labs application notes show how stage-appropriate solid-form work can support screening strategy, form selection, and formulation decisions.
A risk-based guide to defining screening depth around the development stage, decision, and consequences of missing a relevant form instead of relying on experiment count alone.
Download this Application NoteExplains how polymorphs, salts, cocrystals, hydrates, solvates, and amorphous forms can affect solubility, stability, manufacturability, and the selection of a developable form.
Download this Application NoteA nifedipine case study showing how complementary screening and characterization methods can identify amorphous solid-dispersion candidates when solubility and bioavailability limit development.
Download this Application NoteBegin with a focused risk assessment near candidate nomination, before toxicology, formulation, and larger material commitments make a form change more disruptive.
Yes. The first program is designed to prioritize high-value evidence when material is limited. Scope, sample use, decision points, and stop criteria are defined before testing.
No. The pathway depends on ionization, crystallinity, solubility, stability, dose, formulation needs, available material, and the decision the data must support.
The program delivers a recommended development form, an alternative-form strategy, a risk register, and clearly prioritized next experiments.
Yes. Work can continue into crystallization process development, analytical method development, cGMP form testing, release and stability support, and regulatory documentation.
Share the candidate structure or identity, available material, prior solid-state and solubility data, intended route and dose, formulation plan, next milestone, and timeline. We will help define the smallest defensible scope for the next decision.
